anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants must meet criteria for one of the following disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 criteria (52): major depressive disorder (MDD), persistent depressive disorder (PDD), bipolar disorder (BD) type I/type II, cyclothymia. Multiple mood disorders are employed, in line with the Research Domain Criteria (RDoC; (53)) framework and the relative imprecision of current symptom diagnostic clusters for tracking treatment responses and course of disease. To ensure adequate representation across diagnostic categories (including controls), the investigators will cap enrollment of major mood disorders (MDD, BD type I/II) to 50%, PDD and cyclothymia to 25% and recruit a healthy comparison group to comprise the remaining 25% of the sample.
PCT No. PCT/SE95/00117 Sec. 371 Date Jul. 15, 1996 Sec. 102(e) Date Jul. 15, 1996 PCT Filed Feb. 6, 1995 PCT Pub. No. WO95/20945 PCT Pub. Date Aug. 10, 1995The invention relates to a lipophilic carrier preparation having a continuous lipid phase, comprising a polar lipid material in combination with a non-polar lipid, and optionally a polar solvent, wherein the polar lipid material is a galacto-lipid material. The invention also relates to the use of said lipophilic carrier preparation as a carrier for an active substance in a pharmaceutical composition, but also in nutritional, cosmetical and food products, as well as to a pharmaceutical composition. The invention relates to a lipophilic carrier preparation having a continuous lipid phase, comprising a polar lipid material in combination with a non-polar lipid, and optionally a polar solvent, wherein the polar lipid material is a galactolipid material. The invention also relates to the use of said lipophilic carrier preparation as a carrier for an active substance in a pharmaceutical composition, but also in nutritional, cosmetic and food products, as well as to a pharmaceutical composition.
Blacks (African Americans) with Type 2 diabetes (T2DM) have higher prevalence of diabetes, poorer metabolic control, and greater risk for complications and death compared to Whites. Poor outcomes in Blacks with T2DM can be attributed to patient, provider, and health systems level factors. Provider and health system factors account for \<10% of variance in major diabetes outcomes. Key differences appear to be at the patient level. Of the patient level factors, consistent differences between Blacks and Whites with T2DM have been found in diabetes knowledge, self-management skills, empowerment, and perceived control. A variety of interventions to improve diabetes self-management have been tested including: 1) knowledge interventions; 2) lifestyle interventions; 3) skills training interventions; and 4) patient activation and empowerment interventions. Most of these interventions have been tested individually, but rarely have they been tested in combination, especially among Blacks who have the greatest burden of diabetes related complications. This study provides a unique opportunity to address this gap in the literature. Using a 2x2 factorial design, this study will test the efficacy of separate and combined telephone-delivered, diabetes knowledge/information and motivation/behavioral skills training intervention in high risk Blacks with poorly controlled T2DM (HbA1c ≥9%). The primary objective is to test the separate and combined efficacy of a telephone-delivered diabetes knowledge/information intervention and motivation/behavioral skills training intervention in improving HbA1c levels in Blacks with T2DM using a 2x2 factorial design. The secondary objectives are: 1) To determine whether patients randomized to the telephone-delivered diabetes knowledge/information intervention, the motivation/behavioral skills training intervention or the combined intervention will have greater improvement in physical activity, diet, medication adherence, and self-monitoring of blood glucose at 12 months of follow-up compared to usual care; and 2) To determine the cost-effectiveness of each telephone intervention separately, and then in combination. The primary outcome is HbA1c level at 12 months of follow-up. The secondary outcomes are cost-effectiveness of each telephone intervention separately, and then in combination, and change in physical activity, diet, medication adherence, and self-monitoring of blood glucose over 12 months of follow-up. The long-term goal of the project is to achieve improvement in diabetes-related outcomes in this patient population.
Community members will have access to a series of virtual Lunch and Learn podcasts, which will be 30-minute long, pre-recorded sessions in English and/or Spanish. Podcast sessions will cover updated cancer-relevant recommendations from the United States Preventive Services Task Force (USPSTF). Reach will be tracked with number of visits and/or other access metrics.
The aims of our study were to examine whether initial or subsequent adiposity status had a greater effect on hypertension. We collected data in 1992 and again in 2007 from the same group of 597 individuals in the middle age. The subjects were classified into four groups: individuals with a normal body mass index (BMI) in 1992 and 2007 were in Group I; those with a normal BMI in 1992, but became overweight or obese in 2007 were in Group II; those who were overweight or obese in 1992, but had a normal BMI in 2007 were in Group III; and those who were overweight or obese in 1992 and 2007 were in Group IV. Their demographic data were recorded. The relationship between adiposity status and hypertension was analyzed using logistic regression model. The cumulative incidence of hypertension was 35.5%, 56.3%, 50.0%, and 65.1% for Group I to IV, respectively. Compared with Group I, after adjusted factors, the hazard ratio (HR) was 1.80 for Group II (P = .001), 1.40 for Group III (P = .150), and 2.31 for Group IV (P < .001). Adiposity status in 2007 could predict hypertension (OR = 2.5, P < .001), as opposed to the initial adiposity status (P = .148). Subsequently adiposity status could have major effects on hypertension. Our society is very short of public health resources, particularly in developing countries, we should pay more attention to current adiposity status and encourage middle-aged people to lose weight.
This will be a randomized single blind clinical trial. Setting and conduct: Twenty caries free premolar teeth from fifteen patients assigned for orthodontic extraction will be included. Participants including major eligibility criteria: Their parents need to sign an informed form, Patients shouldn't have any systematic complication, The teeth should be free of any symptom, caries and decalcification and should reveal a normal response to pulp sensitivity tests, No mobility or swelling in the surrounding soft tissues, sensitivity on palpation or percussion should be present. Intervention: A class one cavity will be prepared and the depth will be increased until the pulp exposure occurs. One millimeter of the coronal pulp will be removed. Then the exposure site will be covered using two pulpotomy agents: White ProRoot MTA as control group and iRoot BP. After six weeks (42 days) the teeth will be extracted after radiographic and clinical examination to find any sign of swelling, abscess or sinus tract. Main outcome measures (variables): The teeth will be sectioned and examined to compare the presence of dentinal bridge, its thickness and feature in the terms of tunnel defect formation. The underlying pulp will be assessed and graded according to the degree of inflammation as follows: grade 0 no inflammation, grade 1 mild inflammation, grade 2 moderate inflammations, grade 3 severe inflammation, grade 4 abscess formation or necrosis. Our criteria are based on ISO 7405.
Based on the mechanism of action and findings in animals, ADCETRIS can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of ADCETRIS in pregnant women. In animal reproduction studies, brentuximab vedotin caused embryo-fetal toxicities, including significantly decreased embryo viability, and fetal malformations at maternal exposures that were similar to the clinical dose of 1.8 mg/kg every three weeks.

Advise females of reproductive potential to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS. Advise male patients with female partners of reproductive potential to use effective contraception during ADCETRIS treatment and for 4 months after the last dose of ADCETRIS. Advise a pregnant woman of the potential risk to the fetus [see Use in Specific Populations (8.1, 8.3)].
PROBLEM TO BE SOLVED: To efficiently and stably obtain a large amount of a solution of chlorophyll, by automatizing production facilities as much as possible and operating the facilities throughout the year regardless of season without preserving Sasa albo-marginata as a raw material for a long period of time. SOLUTION: Raw Sasa albo-marginata is stabilized with a heated diluted solution of copper sulfate, frozen and preserved after the treatment. The Sasa albo-marginata is treated with a heated diluted solution of acidic sodium sulfite to remove lignin. The Sasa albo-marginata after removal of lignin is cut, treated with a heated diluted solution of caustic soda and the solution containing the treated Sasa albo-marginata is subjected to solid-liquid separation. The prepared alkali solution of chlorophyll of Sasa albo-marginata is neutralized to form an acidic precipitate of chlorophyll of Sasa albo-marginata. The precipitate is dehydrated to recover a pasty acidic chlorophyll of Sasa albo-marginata. The pasty acidic chlorophyll of Sasa albo-marginata is mixed with sodium hydrogencarbonate to prepare a solution of chlorophyll of Sasa albo-marginata.
This protocol proposes to study neurobehavioral and social correlates of treatment response in 200 youth (ages 9-13) with general anxiety disorder (GAD), separation anxiety disorder (SAD), and social phobia (SP). All youth with an anxiety disorder will receive 14 weeks of Cognitive Behavioral Therapy (CBT) or Client Centered Therapy (CCT) for child anxiety disorders. The study combines state-of-the-art measures from affective neuroscience, ecologically valid (EMA) measures of mood and behavior in natural environments, and measures of family and social context within a developmentally framed treatment study. The study design focuses on predictors and mechanisms of treatment response. This protocol will test key features of a "vigilance-avoidance" model focusing on hypotheses that pretreatment neural correlates of affective reactivity will predict treatment response and early changes in emotional processing will correlate with clinical response during treatment. In addition, the protocol examines how affective experiences within the family and social context are associated with treatment response and change across treatment, and how these are associated with and interact with neurobehavioral changes in affective functioning. Taken together these aspects of the study will advance understanding of the neurobehavioral, affective, and social processes that underpin treatment response in ways that will inform the design, refinement, and optimal developmental timing of cognitive behavioral treatments, and thus, decrease the morbidity, mortality, and lifetime impairments from these common disorders in youth.
PROBLEM TO BE SOLVED: To prepare a remarkable health food suitable for ensuring quiet sleep by using composite galenicals as main raw materials in order to suppress factors disturbing the sleeps as much as possible. SOLUTION: This health food for quiet sleep is prepared by mixing dry Panax ginseng, Ginkyo biloba extract powder, dry Formes japonicus, calcium, dry Rehmannia glutinosa stem, dry Eucommia ulmoides leaves, dry Zizyphus vulgaris, dry Glycyrrhiza glabra, dry Citrus unshiu, dry Chrysanthemum morifolium and dry Coix lacrma-jobi in a prescribed ratio and subsequently charging the mixture in the dry state into a tea bag.  For example, 1 pt.wt. of the dry Panax ginseng, 0.07-0.3 pt.wt. of the Ginkyo biloba extract powder, 0.1-0.5 pt.wt. of the dry Formes japonicus, 0.1-1.0 pt.wt. of the calcium, 0.5-3.0 pts.wt. of the dry Rehmannia glutinosa stems, 0.25-0.75 pt.wt. of the dry Eucommia ulmoides leaves, 1.5-3.25 pts.wt. of the dry Zizyphus vulgaris, 0.25-1.0 pt.wt. of the dry Glycyrrhiza glabra, 0.1-0.5 pt.wt. of the dry Citrus unshiu, 0.1-0.5 pt.wt. of the dry Chrysanthemum morifolium and 0.3-2.5 pts.wt. of the dry Coix lacrma-jobi are mixed.
Recent studies have confirmed that pain memory is often accompanied by negative emotions. Electroacupuncture (EA) can block the retrieval of painful memories, thereby alleviating the associated negative behaviors. However, the underlying mechanism is poorly understood. This study revealed that the effect of EA on pain memory-induced negative behaviors is related to the mediation of GABAergic neuron activity and GABA receptor expression in the rostral anterior cingulate cortex (rACC). Previous studies have shown that the rACC is a crucial area for regulating nociceptive behaviors and negative emotions in pain memory models. The GABAergic neurons and receptors in the rACC are largely involved in pain sensation and related effects. However, the relationships among pain memory, GABAergic neurons and receptors in the rACC have not been investigated. In this study, we established a pain memory model via secondary plantar cross-injection of carrageenan and EA treatment. Using chemogenetic methods and behavioral assessments of pain and negative emotion, we found that early excitation of GABAergic neurons in the rACC blocked the recall of pain memories and reduced anxiety-like behaviors in pain memory model rats. Furthermore, pharmacological methods revealed that excitation of GABAA and GABAB receptors in the rACC blocks hyperpathia associated with pain memory and pain-induced anxiety-like behaviors, while inhibition of GABAA and GABAB receptors reverses these effects. These results suggest that EA may alleviate pain and associated anxiety-like behaviors related to pain memories through the activation of GABAergic neurons and excitation of GABAA and GABAB receptors in the rACC.
The present invention relates to a dietotherapeutic vitamin microelement nutrient product and a manufacturing method thereof for preventing synchysis. The product is made of official dietotherapeutic composite vitamins, composite microelements, etc. The present invention has the advantages of low production cost, no environment pollution, no difference on people and age, good taste, less dosage and certain effect and can be easily accepted by patients. Because eyes are windows of the soul and are the most important part in five organs, all the people want a pair of healthy eyes and good eyesight. But nearly half of people in the world have eye diseases, and more than forty million people are blind. If effective measures are not adopted, the number of people having eye diseases can be multiplied, and each person can be threatened by the eye diseases. Posterior vitreous detachment caused by synchysis suddenly happens without any premonition; particularly, macular holes, retinal detachment, vitreous hemorrhage opacity caused by tearing retinal vessels, etc. which seriously damages the most important central vision supervene. Synchysis is easier to happen along with growth of ages, high myopia and light irradiation for a long time. The present invention occupies an important position in the work of preventing and treating blindness; hence, the present invention has very important practical value and far-reaching significance.
Each patient will undergo a 3T MRI scan as well as a dynamic contrast-enhanced CT scan within one week prior to the start of treatment. Patients will also undergo a research 3T MRI scan and research dynamic contrast-enhanced CT scan at the one week post radiotherapy mark. An MRI scan during their 3 month post-treatment follow up visits will take place as per routine standard of care.
The present invention discloses immediate-release red propolis microencapsulates, also called red propolis caseinates, composed of standardized red propolis hydroalcoholic tincture from the bioactive extract, a protein encapsulant, a disintegrant and a flow enhancer. Said dispersing system is composed of a binary system, which, due to its composition, allows immediate release of the active principle. The invention also relates to the process for producing the modified-release red propolis caseinates, by means of the  Spray-Dryer  technique. Furthermore, an embodiment of the invention is disclosed relating to a composition containing the red propolis caseinates in solid formulations, preferably in the form of a powder or in the form of immediate-release hard gelatin capsules. Furthermore, the invention relates to the process for preparing the composition, by confirmation of the production of microscale microcapsules with an immediate-release dissolution profile of 70-110% within a period of 2 hours. Finally, uses are disclosed for the red propolis caseinates and for the powder compositions as nutraceutical and vitamin supplements, chocolate food powders, caffeic supplement powders and pharmaceutical capsules.
Liquid aqueous body cleansing agents with a viscosity of more than 500 mPa.s (20 °C) and containing 4-10 wt. % of a mixture of anionic surfactants, betaine surfactants and non-ionic surfactants, 0.5-2 wt. % of a thickening agent from the group of fatty acid esters of high molecular polyalkylene glycols or polyalkylene glycol ethers and 0.5-1 wt. % solubilized oil constituents and aromatic principles. The inventive body cleansing agents contain a preserving agent which is a combination of sodium benzoate, p-hydroxy benzoic acid esters and phenoxy in a weight ratio of 1 : (0.5-2) : (0.5-2). Said preserving agent does not interfere with the clarified liquidity or viscosity stability of the cleansing agent.
A medication intelligent device is suitable for use with a can body. The can body defines a containing space for containing at least one medicine. The medication intelligent device contains a cover and an auxiliary medicine deliver. The cover is detachably mounted on the can body. The auxiliary medicine deliver is disposed on the cover and includes a main control chip and a gate electrically connected to the main control chip; wherein the main control chip is used to make the gate move between a closed position and an opened position relative to the cover. At the closed position, the gate closes the containing space. At the opened position, the gate opens the containing space.
During marketing of Zoloft and other SSRIs and SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g. paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms.

Patients should be monitored for these symptoms when discontinuing treatment with Zoloft. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate (see DOSAGE AND ADMINISTRATION).
PURPOSE:To obtain a pack cosmetic giving excellent fitting feeling to the skin, forming soft, flexible and easily peelable film on the skin, leaving moist and smooth skin after peeling and safe to the skin, by compounding a carboxyl- modified polyvinyl alcohol to a cosmetic base. CONSTITUTION:A monomer having 1-2 carboxyl groups (e.g. acrylic acid, maleic anhydride, fumaric acid, etc.) is copolymerized with vinyl acetate and the obtained copolymer is saponified to obtain a modified PVA. The above process is carried out by a semi-batch process wherein the carboxyl-containing monomer is added in the latter stage to uniformize the copolymer composition. The carboxyl-modified PVA having a polymerization degree of 600-2,400 and produced by this process is compounded to a cosmetic base at a solid concentration of 5-30wt%.
In Part 1, cohorts of three to six subjects will receive doses of MGCD0103 administered orally three times per week (TIW) in combination with 60 mg/m2 IV docetaxel administered as a 1-hour infusion on Day 1 of each 3-week (21-day) cycle. The starting dose of MGCD0103 in Part 1 will be 50 mg (approximately 25 mg/m2).
Patients will perform two PET-MRI scans: (1) during cluster period and (2) during pain-free remission period. Scans during cluster periods will aim to acquire data before, during and after crisis. Sumatriptan 6mg will be injected subcutaneously under PET-MRI camera to relieve patient pain.
The intestinal microbiome influences growth and disease progression in children with cystic fibrosis (CF). Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA), the newest pharmaceutical modulator for CF, restores the function of the pathogenic mutated CF transmembrane conductance regulator (CFTR) channel. We performed a single-center longitudinal analysis of the effect of ELX/TEZ/IVA on the intestinal microbiome, intestinal inflammation, and clinical parameters in children with CF. Following ELX/TEZ/IVA, children with CF had significant improvements in body mass index and percent predicted forced expiratory volume in one second, and required fewer antibiotics for respiratory infections. Intestinal microbiome diversity increased following ELX/TEZ/IVA coupled with a decrease in the intestinal carriage of Staphylococcus aureus, the predominant respiratory pathogen in children with CF. There was a reduced abundance of microbiome-encoded antibiotic resistance genes. Microbial pathways for aerobic respiration were reduced after ELX/TEZ/IVA. The abundance of microbial acid tolerance genes was reduced, indicating microbial adaptation to increased CFTR function. In all, this study represents the first comprehensive analysis of the intestinal microbiome in children with CF receiving ELX/TEZ/IVA.IMPORTANCECystic fibrosis (CF) is an autosomal recessive disease with significant gastrointestinal symptoms in addition to pulmonary complications. Recently approved treatments for CF, CF transmembrane conductance regulator (CFTR) modulators, are anticipated to substantially improve the care of people with CF and extend their lifespans. Prior work has shown that the intestinal microbiome correlates with health outcomes in CF, particularly in children. Here, we study the intestinal microbiome of children with CF before and after the CFTR modulator, ELX/TEZ/IVA. We identify promising improvements in microbiome diversity, reduced measures of intestinal inflammation, and reduced antibiotic resistance genes. We present specific bacterial taxa and protein groups which change following ELX/TEZ/IVA. These results will inform future mechanistic studies to understand the microbial improvements associated with CFTR modulator treatment. This study demonstrates how the microbiome can change in response to a targeted medication that corrects a genetic disease.